| Literature DB >> 21497126 |
Pedro B S Pedrosa1, Telma A O Cardoso.
Abstract
OBJECTIVES: To compare modes and sources of infection and clinical and biosafety aspects of accidental viral infections in hospital workers and research laboratory staff reported in scientific articles.Entities:
Mesh:
Year: 2011 PMID: 21497126 PMCID: PMC7110847 DOI: 10.1016/j.ijid.2011.03.005
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
Summary table for accidental infections with arboviruses in the laboratory and hospital settings: total number of cases analyzed, overview of percentages according to the main modes of infection, and clinical development characteristics
| Setting | Genus | Virus | Transmission route | Clinical development | Total number of cases | Ref. | ||
|---|---|---|---|---|---|---|---|---|
| Percutaneous | Aerosol exposure/ inhalation | Mucocutaneous | ||||||
| Laboratory | Alphavirus | WEEV | 50 | 50 | 50 | Lethal (100) | 2 | |
| VEEV | 100 | Normal | 12 | |||||
| CHIKV | 100 | Normal | 1 | |||||
| MAYV | 100 | Normal | 1 | |||||
| Total cases | 6 | 94 | 6 | (See above) | 16 | |||
| Flavivirus | LIV | 75 | 25 | 4 | ||||
| TBEV | 100 | Unapparent to severe | 4 | |||||
| KFDV | 100 | Normal to severe | 3 | |||||
| SLEV | 100 | Not described | 1 | |||||
| WNV | 66 | 33 | Normal | 3 | ||||
| Total cases | 33 | 66 | (See above) | 15 | ||||
| Phlebovirus (Bunyaviridae) | RVFV | 100 | Long incubation period | 1 | ||||
| Vesiculovirus (Rhabdoviridae) | Piry | 100 | Normal | 6 | ||||
| Total laboratory cases | (See above) | 38 | ||||||
| Hospital | Flavivirus | DENV | 83 | 17 | Normal | 6 | ||
| YFV | 100 | Severe (lethal) | 1 | |||||
| Total cases | 71.5 | 28.5 | (See above) | 7 | ||||
| Nairovirus | CCHFV | 100 | Normal (hemorrhagic fever in all, lethal in two cases) | 5 | ||||
| Total hospital cases | 41.6 | 58 | (See above) | 12 | ||||
WEEV, western equine encephalitis virus; VEEV, Venezuelan equine encephalitis virus; CHIKV, chikungunya virus; MAYV, Mayaro virus; LIV, louping ill virus; TBEV, tick-borne encephalitis virus; KFDV, Kyasanur Forest disease virus; SLEV, Saint Louis encephalitis virus; WNV, West Nile virus; RVFV, Rift Valley fever virus; DENV, dengue virus; YFV, yellow fever virus; CCHFV, Crimean-Congo hemorrhagic fever virus.
Refers to the same case.
Comparison was impossible as there is no reference for the normal clinical development.
Refers to the only case whose mode of infection was established.
Summary table for infections with airborne viruses in the laboratory and hospital settings: total number of cases analyzed, overview of percentages according to the main modes of infection, and clinical development characteristics
| Setting | Family | Virus | Mode of transmission | Clinical development | Total number of cases | Ref. | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Percutaneous | Aerosol exposure/ inhalation | Droplet inhalation | Mucocutaneous | Oral | ||||||
| Laboratory | Arenaviridae | LCMV | 50 | 50 | Normal to severe (meningo-encephalitis) | 2 | ||||
| Sabia | 100 | Normal | 2 | |||||||
| Machupo | 100 | Not described | 1 | |||||||
| Total cases | 20 | 80 | (See above) | 5 | ||||||
| Bunyaviridae | Hantavirus | 1.3 | 98.7 | Normal to severe (one death and one HFRS with DIC) | 149 | |||||
| Coronaviridae | SARS-CoV | 100 | Mild | 1 | ||||||
| Orthomyxoviridae | Influenza B | 100 | Conjunctivitis (atypical) | 1 | ||||||
| Picornaviridae | Coxsackievirus | 50 | 25 | 25 | Normal to atypical (one with nausea and diarrhea) | 4 | ||||
| Total laboratory cases | 2 | 96 | 0.6 | 0.6 | 0.6 | (See above) | 160 | |||
| Hospital | Arenaviridae | Machupo | 33 | 66 | Normal (lethal for two of the cases) | 3 | ||||
| LCMV | 100 | Extremely mild | 21 | |||||||
| Total cases | 4 | 88 | 8 | (See above) | 24 | |||||
| Coronaviridae | SARS-COV | 100 | Normal | 13 | ||||||
| Total hospital cases | 2.7 | 56.8 | 35.1 | 5.4 | (See above) | 37 | ||||
LCMV, lymphocytic choriomeningitis virus; HFRS, hemorrhagic fever with renal syndrome; DIC, disseminated intravascular coagulation; SARS-CoV; severe acute respiratory syndrome coronavirus.
Summary table for infections with blood-borne viruses in the laboratory and hospital settings: total number of cases analyzed, overview of percentages according to the main modes of infection, and clinical development characteristics
| Setting | Family | Virus | Mode of transmission | Clinical development | Total number of cases | Ref. | ||
|---|---|---|---|---|---|---|---|---|
| Percutaneous | Aerosol exposure/ inhalation | Mucocutaneous | ||||||
| Laboratory | Parvoviridae | Parvo-B19 | 100 | 9 | ||||
| Retroviridae | HIV-1 | 75 | 25 | Normal (seropositivity) | 4 | |||
| Total laboratory cases | 23 | 77 | (See above) | 13 | ||||
| Hospital | Retroviridae | HIV-1 | 98 | 2 (8) | Normal | 91 | ||
| Parvoviridae | Parvo-B19 | 100 | 8 | |||||
| Flaviviridae | HCV | 98 | 2 | Normal to atypical (see | 51 | |||
| HGV | 100 | Unapparent | 1 | |||||
| Total cases | 98 | 2 | (See above) | 52 | ||||
| Hepadnaviridae | HBV | 50 | 50 | Normal to severe (one fulminant hepatitis) | 2 | |||
| Deltaviridae | HDV | 100 | Normal (acute hepatitis after 90 days) | 1 | ||||
| Total hospital cases | 93 | 7 | (See above) | 152 | ||||
Parvo-B19, parvovirus B19; HIV, human immunodeficiency virus; HCV, hepatitis C virus; HGV, hepatitis G virus; HBV, hepatitis B virus; HDV, hepatitis D virus (delta virus).
Two percent refers to cases of mucocutaneous mode of infection only, and 8% refers to simultaneous mucocutaneous and percutaneous modes of infection.
Refers to a single case of simultaneous infection with HIV and HCV.
Refers to a single case of simultaneous infection with HBV and HDV.
Refers to cases with mucocutaneous mode of infection only.
Special cases of accidental blood-borne virus infection
| Virus | Number of cases | Mode of infection | Clinical presentation | Ref. |
|---|---|---|---|---|
| HCV | 3 | Percutaneous | Short period of incubation (9 days to 2 weeks) | |
| HGV | 1 | Percutaneous | Unapparent | |
| HIV | 1 | Aerosol contact/inhalation | Seroconversion | |
| HBV | 1 | Mucocutaneous | Fulminant hepatitis |
HCV, hepatitis C virus; HGV, hepatitis G virus; HIV, human immunodeficiency virus; HBV, hepatitis B virus.
Summary table for accidental infections with viruses with preferential mucocutaneous transmission in the laboratory and hospital settings: total number of cases analyzed, overview of percentages according to the main modes of infection, and clinical development characteristics
| Environment | Family | Virus | Mode of transmission | Clinical development | Total number of cases | Ref. | ||
|---|---|---|---|---|---|---|---|---|
| Percutaneous | Aerosol exposure/ inhalation | Mucocutaneous | ||||||
| Laboratory | Herpesviridae | McHV1 | 66 | 33 | Normal | 3 | ||
| Orthopoxviridae | VACV | 50 | 50 | Normal | 4 | |||
| Arenaviridae | Lassa | 100 | Normal | 1 | ||||
| Total laboratory cases | 50 | 12.5 | 37.5 | 8 | ||||
| Hospital | Herpesviridae | HSV-1 | 100 | Normal | 1 | |||
| HZV | 100 | Normal | 1 | |||||
| Arenaviridae | Lassa | 100 | Normal | 1 | ||||
| Filoviridae | MARV | 100 | Atypical mild (uveitis and thrombocytopenia) | 1 | ||||
| Total hospital cases | 75 | 25 | 4 | |||||
McHV1, Macacine herpesvirus 1; VACV, vaccinia virus; HSV-1, herpes simplex virus 1; HZV, herpes zoster virus; MARV, Marburg virus.
Possible involvement of aerosol as source in one case of mucocutaneous mode of infection.
Possible contact with infected secretions in addition to infective aerosol exposure.